NCT03329560View on ClinicalTrials.gov

Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 12, 2018

Primary Completion Date

October 8, 2019

Study Completion Date

October 8, 2019

Conditions
HIV-1-infection
Interventions
BIOLOGICAL

Oral fecal microbiota transplantation

All subjects will receive one dose per week for 6 weeks (6 total doses) of PRIM-DJ2727 oral capsules containing lyophilized microbiota product derived from 150 grams of healthy donor stool.

Trial Locations (1)

77009

Thomas Street Health Center, Houston

All Listed Sponsors
lead

The University of Texas Health Science Center, Houston

OTHER

NCT03329560 - Safety of FMT Using Oral Encapsulated PRIM-DJ2727 in HIV | Biotech Hunter | Biotech Hunter